Home › Funds › Crossmark Global Holdings, Inc. › ABT

Crossmark Global Holdings, Inc. position in ABT

ABBOTT LABORATORIES · Health Care

Crossmark Global Holdings, Inc. reported holding 368,095 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$36.4M, representing 0.47% of its reported portfolio and ranking #44 among its reported holdings. Crossmark Global Holdings, Inc. has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)368.10K sh
Reported value held$36.38M
Portfolio Weight0.47%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Crossmark Global Holdings, Inc.'s ABT position evolved

Crossmark Global Holdings, Inc. first disclosed a stake in ABT in Q3 2023 at 320,744 shares (US$31.3M). The position peaked in Q3 2025 at 300,773 shares, worth US$40.3M. Across 13 filings, Crossmark Global Holdings, Inc. increased the stake 9 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 368,095 shares valued at US$36.4M — an increase of 46,248 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 320.74K $31.29M New
Q4 2023 348.27K $38.33M Add
Q1 2024 331.56K $37.69M Reduce
Q2 2024 333.22K $34.62M Add
Q3 2024 338.27K $38.57M Add
Q4 2024 338.88K $38.33M Hold
Q1 2025 272.84K $36.19M Reduce
Q2 2025 288.40K $39.23M Add
Q3 2025 300.77K $40.29M Add
Q4 2025 305.22K $38.24M Add
Q1 2026 313.08K $32.14M Add
Q2 2026 321.85K $29.20M Add
Q3 2026 368.10K $36.38M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Crossmark Global Holdings, Inc. held ABT?

Crossmark Global Holdings, Inc. has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Crossmark Global Holdings, Inc.'s current position in ABT?

As of Q3 2026, Crossmark Global Holdings, Inc. holds 368.10K shares of ABT (ABBOTT LABORATORIES), valued at $36.38M, representing 0.47% of its reported portfolio and ranking #44.

Has Crossmark Global Holdings, Inc. been buying or selling ABT?

In the latest 13F filing (Q3 2026), Crossmark Global Holdings, Inc. increased its position in ABT. The position peaked in Q3 2025 at 300.77K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.